VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $359,911,596 | +2.1% | 7,060,588 | +0.0% | 0.24% | +7.8% |
| Q2 2023 | $352,559,989 | +32.0% | 7,059,751 | -1.0% | 0.22% | +24.4% |
| Q1 2023 | $267,146,529 | -6.7% | 7,127,611 | +19.3% | 0.18% | -14.1% |
| Q4 2022 | $286,454,808 | +162.8% | 5,974,139 | -34.2% | 0.20% | +150.0% |
| Q3 2022 | $109,016,908 | +18.6% | 9,075,502 | +114.8% | 0.08% | +30.2% |
| Q2 2022 | $91,935,000 | -12.1% | 4,224,487 | -2.4% | 0.06% | +26.0% |
| Q1 2022 | $104,556,000 | +3.5% | 4,329,764 | +2.0% | 0.05% | +19.0% |
| Q4 2021 | $101,035,000 | -2.7% | 4,246,664 | +3.7% | 0.04% | -6.7% |
| Q3 2021 | $103,851,000 | +12.1% | 4,093,466 | -0.6% | 0.04% | +12.5% |
| Q2 2021 | $92,673,000 | +10.9% | 4,116,959 | -2.7% | 0.04% | +5.3% |
| Q1 2021 | $83,547,000 | -22.3% | 4,230,307 | +0.8% | 0.04% | -24.0% |
| Q4 2020 | $107,538,000 | -46.2% | 4,196,778 | +0.0% | 0.05% | -51.9% |
| Q3 2020 | $199,839,000 | +42.8% | 4,196,429 | -11.2% | 0.10% | +31.6% |
| Q2 2020 | $139,934,000 | – | 4,725,792 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |